UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 28, 2013
Date of Report
April 30, 2013
(Date of earliest event reported)
BIOZOOM, INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-53678 | 26-0370478 |
(State or other jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Wilhelmshoeher Allee 273A
Kassel, Germany, 34131
(Address of principal executive offices, including zip code)
800-882-1683
(Registrants telephone number, including area code)
N/A
(Former name, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
ITEM 8.01 OTHER EVENTS.
On April 30, 2013, the registrant Biozoom, Inc.s wholly owned subsidiary, Biozoom Technologies, Inc., (the Company) entered into a Scientific Advisory Board Consulting Agreement with Prof. Dr. Hasan Mukhtar. Under the agreement, Prof. Dr. Mukhtar agreed to provide consulting services related to the field of dermatology up to twelve (12) days per year, attend meetings with other Scientific Advisory Board members, and earn 25,000 restricted common shares of the registrants common stock 180 days after execution of the agreement, as well as an option to purchase 25,000 restricted common shares of the registrants common stock each quarterly period following execution, at the closing market price on the first day of such period. The agreement has an initial term of 360 days, is renewable for successive one-year periods upon mutual agreement of the parties, and can be terminated by either party after providing the other 90 days notice.
On May 5, 2013, the Company entered into a Scientific Advisory Board Consulting Agreement with Prof. Dr. Rudolf Kessler, Steinbeis Transferzentrum Prozesskontrolle und Datenanalyse. Under the agreement, Prof. Dr. Kessler agreed to provide consulting services related to the fields of spectroscopy and multivariate data analysis up to twelve (12) days per year, attend meetings with other Scientific Advisory Board members, and earn 25,000 restricted common shares of the registrants common stock 180 days after execution of the agreement, as well as an option to purchase 25,000 restricted common shares of the registrants common stock each quarterly period after execution, at the closing market price on the first day of such period. The agreement has an initial term of 360 days, is renewable for successive one-year periods upon mutual agreement of the parties, and can be terminated by either party after providing the other 90 days notice.
On May 8, 2013, the Company entered into a Scientific Advisory Board Consulting Agreement with Prof. Dr. Leonard Zastrow. Under the agreement, Prof. Dr. Zastrow agreed to provide consulting services related to the field of cosmetics (specifically the use of antioxidants in cosmetics, including in anti-aging and sunscreen cosmetics) up to twelve (12) days per year, attend meetings with other Scientific Advisory Board members, and earn 25,000 restricted common shares of the registrants common stock 180 days after execution of the agreement, as well as an option to purchase 25,000 restricted common shares of the registrants common stock each quarterly period after execution, at the closing market price on the first day of such period. The agreement has an initial term of 360 days, is renewable for successive one-year periods upon mutual agreement of the parties, and can be terminated by either party after providing the other 90 days notice.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Dated: May 28, 2013 | BIOZOOM, INC. | |
|
|
|
| By: | /s/ Hardy Hoheisel Name: Hardy Hoheisel Title: Chief Executive Officer |